Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

NCT07012304 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG: Gecacitinib Hydrochloride Tablets

Sponsor

Yujun DONG